NovaBay Sells Eyecare Business, Adjourns Shareholder Meeting

TL;DR

NovaBay sold its Eyecare biz to PRN and punted the shareholder meeting. Big changes afoot.

AI Summary

NovaBay Pharmaceuticals, Inc. filed a DEFA14A on January 23, 2025, announcing the completion of its Eyecare business sale to PRN. The company also announced the adjournment of its Special Meeting of Stockholders, with the new meeting date to be announced later. This filing indicates a significant strategic shift for NovaBay as it divests a business segment.

Why It Matters

This filing signals a major strategic change for NovaBay Pharmaceuticals, indicating a divestiture of its Eyecare business and a potential refocusing of its operations. Investors should monitor future announcements regarding the company's new strategic direction.

Risk Assessment

Risk Level: medium — The sale of a business segment and adjournment of a shareholder meeting can indicate uncertainty or ongoing strategic adjustments, which may present risks to investors.

Key Numbers

• 20250123 — Filing Date (Date of the DEFA14A filing)
• 1231 — Fiscal Year End (NovaBay's fiscal year end date)

Key Players & Entities

• NovaBay Pharmaceuticals, Inc. (company) — Registrant
• PRN (company) — Buyer of Eyecare Business
• 0001389545 (company) — Central Index Key for NovaBay Pharmaceuticals
• 2000 POWELL STREET, SUITE 1150 (location) — Business and Mail Address for NovaBay
• EMERYVILLE (location) — City for NovaBay's Address
• 94608 (location) — ZIP Code for NovaBay's Address

FAQ

Key Financial Figures

• $11.5 million — enova eyecare business by approving the $11.5 million asset sale Reconvened Special Meeting

Filing Documents

• nby20250123_defa14a.htm (DEFA14A) — 31KB
• logo.jpg (GRAPHIC) — 4KB
• 0001437749-25-001633.txt ( ) — 37KB

Forward-Looking Statements

Forward-Looking Statements This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are based upon the Company and its management's current expectations, assumptions, estimates, projections and beliefs. Such statements include, but are not limited to, statements regarding the Asset Sale and its completion pursuant to the Asset Purchase Agreement, by and between PRN and the Company, dated as of September 19, 2024 and as amended on November 5, 2024, the potential Dissolution of the Company and related matters. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in, or implied by, these forward-looking statements. Other risks relating to NovaBay's business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company's latest Form 10-K, subsequent Forms 10-Q and/or Form 8-K filings with the SEC and the Special Meeting Proxy Statement, as supplemented including by the Supplement to the Special Meeting Proxy Statement dated as of November 12, 2024, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law. Additional Information and Where to Find It In connection with the solicitation of proxies, on October 16, 2024, NovaBay filed the Special Meeting Proxy Statement with the SEC with respect

View Full Filing

View this DEFA14A filing on SEC EDGAR